What is BETAHISTINE?

BETAHISTINE 24 MG contains BETAHISTINE HYDROCHLORIDE : 24 MG. It is listed in the Health Canada Drug Product Database under DIN 02466457, held by SANIS HEALTH INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 23-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is BETAHISTINE used for?

BETAHISTINE (betahistine dihydrochloride) is indicated for: reducing the episodes of recurrent vertigo associated with Ménière's disease.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

How is it administered?

The usual daily dosage range is 24-48 mg administered orally in divided doses. Three Times Daily Dosing: 8 mg tablets: 1 to 2 tablets three times daily. 16 mg tablets: ½ to 1 tablet three times daily. Twice Daily Dosing 24 mg tablets: 1 tablet twice daily. Missed Dose If a dose is missed, the missed dose should not be taken. The next dose should be taken at the usual time. A double dose should never be taken to make up for a forgotten dose. For management of a suspected drug overdose, contact your regional Poison Control Centre. A few overdose cases (up to 640 mg), with mild to moderate symptoms of nausea, dry mouth, dyspepsia, abdominal pain and somnolence have been reported. Presumably, more serious complications (e.g. convulsion, pulmonary or cardiac complications) may occur in cases of intentional overdose of BETAHISTINE (betahistine dihydrochloride) above 640 mg, especially in combination with other overdosed drugs. Standard overdose protocol / supportive measures should be followed.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store tablets at controlled room temperature (15-30°C) and protect from exposure to heat and moisture.

How is it supplied?

BETAHISTINE (betahistine dihydrochloride) 8 mg, 16 mg and 24 mg tablets contain 8 mg, 16 mg and 24 mg of betahistine dihydrochloride respectively. BETAHISTINE (betahistine dihydrochloride) tablets are available as follows: 8 mg tablets: White to almost white, round, flat-faced, bevelled-edge tablets, engraved "N" on one side and "8" on the other side. 16 mg tablets: White to almost white, round, biconvex, scored tablets, engraved "N" on one side and "16" on the scored side. 24 mg tablets: White to almost white, round, biconvex, scored tablets, engraved "N" on one side and "24" on the scored side. BETAHISTINE (betahistine dihydrochloride) 8 mg, 16 mg and 24 mg tablets are available in bottles of 100 tablets and 16 mg and 24 mg tablets are available in blisters of 100 tablets.

Contraindications

BETAHISTINE is contraindicated in: • patients with known hypersensitivity to betahistine or to any of the tablet constituents. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section. • patients with peptic ulcer and in patients with a history of this condition (see WARNINGS AND PRECAUTIONS, Gastrointestinal). • patients with pheochromocytoma.

Warnings and precautions

Respiratory Although clinical intolerance to betahistine dihydrochloride tablets has been shown in a relatively few patients with bronchial asthma, caution should be exercised when giving the product to asthmatic patients. Gastrointestinal Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using betahistine dihydrochloride tablets. Although experiments in animals and in humans have shown that the gastrointestinal side effects associated with betahistine dihydrochloride are not related to gastric acid production, BETAHISTINE is contraindicated in the presence of patients with peptic ulcer and in patients with a history of this condition. Pregnant Women The safety of betahistine dihydrochloride in human pregnancy has not been established. Animal studies are insufficient with respect to effects on pregnancy, embryonal / foetal development, parturition and postnatal development. The potential risk for humans is unknown. Betahistine dihydrochloride should not be used during pregnancy unless the potential benefits to the mother outweigh the potential risk to the fetus. Nursing Women There are no clinical studies of the excretion of betahistine dihydrochloride into human milk. Betahistine accumulates in the milk of lactating rat dams.The importance of the drug to the mother should be weighed against the benefits of nursing and the potential risks for the child. Effect on Ability to Drive and Use Machines Although not studied in patients with Ménière's disease, in clinical studies using normal healthy volunteers without Ménière's disease, 72 mg of betahistine dihydrochloride taken three times daily for three days, had no or negligible effects on driving skills in a driving task. However, Ménière's disease itself can negatively affect the ability to drive and use machines.

What can be used instead?

Other Canadian products sharing ATC code N07CA01 BETAHISTINE. 17 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

Who else supplies BETAHISTINE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. BETAHISTINE appears in 113 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.